Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

Rhea-AI Summary

Shineco (NASDAQ: SISI) has formed a strategic partnership with Singapore-based BICC Pte Ltd to advance their blockchain-based cell asset ecosystem. The collaboration focuses on implementing and redeeming "on-chain cell assets" across multiple institutions, marking a transition from technical integration to real-world applications.

The partnership builds on Shineco's previous initiatives, including establishing a Cell Digital Division and acquiring a 51% stake in Xi'an Dong'ao Health Management. Plus Me will provide digital management for Shineco's stem cells on Ethereum, while BICC will integrate its iPSC stem cell storage services into Shineco's blockchain system. The collaboration leverages BICC's network of 3,000+ sales representatives and their expertise in wound-healing solutions, cell banking, and exosome delivery technology.

Positive

• Strategic partnership with BICC expands global reach and service capabilities
• Access to BICC's extensive network of 3,000+ sales representatives
• Integration of BICC's validated technologies enhances product portfolio
• 51% acquisition of Xi'an Dong'ao strengthens operational infrastructure

Negative

• Complex regulatory compliance requirements across multiple jurisdictions
• Technical challenges in blockchain integration and standardization
• Dependency on multiple partners for ecosystem success

BEIJING, Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application.

This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division,signing an agreement with Plus Me Limited for on-chain cell asset management and marketing ecosystems, and acquiring a 51% stake in Xi'an Dong'ao Health Management Co., Ltd. These efforts lay a solid foundation for the digital application of cell assets. The two parties will collaborate on standard-setting, compliance coordination, and scenario exploration to transition the project from "technical feasibility" to "verifiable applicability."Under the cooperation framework, Plus Me will provide full-lifecycle digital management for Shineco's compliant mesenchymal stem cells on the Ethereum mainnet, generating"digital identities" and issuing ERC-1400/ERC-20 standard "Cell Reimbursement Vouchers." Following the collaboration with BICC, BICC's iPSC stem cell storage services will be integrated into Shineco's blockchain system. Users holding" Cell Reimbursement Vouchers" will be able to redeem them in designated BICC scenarios, forming a cross-enterprise service

On the offline support front, Shineco has established a "storage + reinfusion" network through the acquisition of Xi'an Dong'ao Health (specializing in stem cell/immune cell storage and health management). BICC's distribution network (3,000+ sales representatives) will serve as extended nodes of this network, allowing users to complete voucher verification and cell therapy services at BICC's Asian service centers. This addresses the inefficiencies of traditional cross-regional cell service circulation. Additionally, BICC's clinically validated wound-healing solutions, serum-free media patents, cell banking services, iPSC-derived therapies and exosome delivery technology will synergize with Shineco's extracellular vesicle-derived products business, with technical parameters incorporated into the blockchain asset valuation system to enhance the technical endorsement of on-chain assets.

In terms of division of responsibilities, Shineco will focus on cell quality and offline network standardization, while BICC will emphasize user services and scenario integration. Both parties will collaborate with technical partners to adapt on-chain modules and compliance tools, ensuring all initiatives strictly adhere to local regulations and internal risk controls. Shineco assumes full responsibility for cell quality, Plus Me ensures on-chain compliance, and BICC contributes its scientist team and medical resources to participate in standardizing cell assets. The three parties will ensure end-to-end compliance for on-chain cell assets—from storage and circulation to application supporting Shineco's vision of "building a decentralized biological cell marketing ecosystem."

Jennifer Zhan, CEO of Shineco, stated, "The collaboration with BICC will tightly integrate 'standards and scenarios,' exploring verifiable application paths within a compliance framework. Shineco is transitioning from a single technical service provider to a global cell economy infrastructure provider. We welcome more biological cell companies to join the ecosystem and will continue to update on project progress."

About BICC Pte Ltd

Founded in 2024, BICC is an innovative biotechnology holding company that unites a world-class team of scientists and medical experts specializing in stem cell treatments and artificial intelligence. With a strategic presence across Asia—including offices in China, Thailand, and Singapore—BICC leverages its proprietary stem cell technologies, such as patented serum-free media, iPSC-derived therapies, and clinically proven wound-healing applications, alongside personalized cell banking services. This expertise is enhanced by a suite of science-backed wellness offerings, including regenerative treatments, anti-aging supplements, and exosome-based cosmetics, positioning BICC at the cutting edge of integrated health solutions. For more information about BICC, please visit www.BICC.sg.

About Shineco, Inc.

Shineco, Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. The Company's core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information about Shineco, please visit www.biosisi.com/.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.

For more information, please contact:

Shineco,Inc.
secretary@shineco.tech
Mobile: +86-010-68130220

 

View original content:https://www.prnewswire.com/news-releases/shineco-nasdaq-sisi--bicc-from-tech-on-chain-to-global-redeemabilityrwa-ecosystem-takes-off-for-long-term-growth-302538261.html

SOURCE Shineco,Inc.

FAQ

What is the strategic partnership between Shineco (NASDAQ: SISI) and BICC?

The partnership aims to implement and redeem 'on-chain cell assets' across multiple institutions, transitioning from technical blockchain integration to real-world applications in cell asset management.

How will BICC's network benefit Shineco's operations?

BICC's network of 3,000+ sales representatives will serve as extended nodes for Shineco's storage and reinfusion network, enabling voucher verification and cell therapy services across Asian service centers.

What is Shineco's role in the partnership with BICC?

Shineco will focus on cell quality and offline network standardization, while maintaining responsibility for cell quality in the ecosystem. They aim to build a decentralized biological cell marketing ecosystem.

How does the blockchain integration work in Shineco's cell asset system?

Plus Me provides full-lifecycle digital management for Shineco's stem cells on the Ethereum mainnet, generating digital identities and issuing ERC-1400/ERC-20 standard Cell Reimbursement Vouchers that can be redeemed in BICC scenarios.

What recent acquisitions has Shineco (SISI) made to strengthen its position?

Shineco acquired a 51% stake in Xi'an Dong'ao Health Management, which specializes in stem cell/immune cell storage and health management, establishing a 'storage + reinfusion' network.